Evidence map›Paper›PMID 31637475›Full record

ArticleCancer immunology, immunotherapy : CII2019

Pembrolizumab for anaplastic thyroid cancer: a case study.

Marra Jai Aghajani, Adam Cooper, Helen McGuire, Thomas Jeffries, Jawad Saab, Kasim Ismail, Paul de Souza, Victoria Bray, Barbara Fazekas de St Groth, Navin Niles and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Tumor-Infiltrating CD4Journal of inflammation research · 2022
    Article
  15. Review
  16. Advances in targeted therapy for anaplastic thyroid carcinoma.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2021
    Review
  17. Article
  18. Anaplastic thyroid cancer: outcomes of trimodal therapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2021
    Article
  19. Review
  20. Tissue Factor-Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Marra Jai AghajaniIngham Institute for Applied Medical Research, 1 Campbell St, Liverpool, NSW, 2170, Australia. 17691938@student.westernsydney.edu.au.ORCID http://orcid.org/0000-0002-8088-4509
Adam CooperSchool of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
Helen McGuireDiscipline of Pathology, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Thomas JeffriesHawkesbury Institute for the Environment, Western Sydney University, Penrith, NSW, Australia.
Jawad SaabSydney South West Pathology Services, Liverpool Hospital, Liverpool, NSW, Australia.
Kasim IsmailSchool of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
Paul de SouzaIngham Institute for Applied Medical Research, 1 Campbell St, Liverpool, NSW, 2170, Australia.
Victoria BrayLiverpool Cancer Therapy Centre, Corner of Goulburn and Elizabeth Streets, Liverpool, NSW, 2170, Australia.
Barbara Fazekas de St GrothDiscipline of Pathology, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Navin NilesIngham Institute for Applied Medical Research, 1 Campbell St, Liverpool, NSW, 2170, Australia.
Tara Laurine RobertsIngham Institute for Applied Medical Research, 1 Campbell St, Liverpool, NSW, 2170, Australia.
Camden and Campbelltown Hospitals · AULiverpool Hospital · AUThe University of Sydney · AUWestern Sydney University · AU

Funding

Cancer Council NSW APP1147099Cancer Institute New South Wales Future Research Leader Fellowship -HMM Early Career Fellowship GNT1037298
6 · The paper itself

Abstract

Blockade of the PD-1/PD-L1 pathway with targeted monoclonal antibodies has demonstrated encouraging anti-tumour activity in multiple cancer types. We present the case of a patient with BRAF-negative stage IVC anaplastic thyroid cancer (ATC) treated with the anti-PD-1 monoclonal antibody, pembrolizumab, following radiographic progression on chemoradiation. Blood samples were collected prior to and at four time points during treatment with pembrolizumab. Mass cytometry was used to determine expression of relevant biomarkers by peripheral blood mononuclear cells. Faecal samples were collected at baseline and 4 weeks following treatment initiation; taxonomic profiling using 16S ribosomal RNA (rRNA) gene sequencing was performed. Following treatment, a marked expansion in CD20

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsBacteroidesB-LymphocytesCD4-Positive T-LymphocytesFecesHumansKiller Cells, NaturalMaleMicrobiotaMiddle AgedProgrammed Cell Death 1 ReceptorRNA, Ribosomal, 16SThyroid Carcinoma, AnaplasticThyroid NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 ReceptorRNA, Ribosomal, 16SAnaplastic thyroid cancer (ATC)Anti-PD-1 antibodyCheckpoint inhibitorPembrolizumab

Identifiers

PMID31637475
PMCPMC11028133
OpenAlexW2981492940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.